{"title":"UCB Accesses Brazilian Market by Acquiring Majority Stake in Meizler Biopharma","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I6.1751","DOIUrl":null,"url":null,"abstract":"UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"41 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I6.1751","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
UCB Pharma has agreed to acquire a 51% majority stake in privately held Meizler Biopharma in order to make a direct entry into the Brazilian pharmaceutical market. Although the specific financial details of the transaction were not disclosed, Meizler’s owners are entitled to performance-related milestone payments and UCB has an option to purchase the remaining 49% in the future. The deal is the latest example of a global pharmaceutical company targeting Brazil for expansion.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
